Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Praxis Precision Medicines, Inc. (PRAX)

1.475   0.06 (4.24%) 09-26 15:33
Open: 1.42 Pre. Close: 1.415
High: 1.51 Low: 1.42
Volume: 317,278 Market Cap: 190(M)

Technical analysis

as of: 2023-09-26 3:21:45 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 1.84     One year: 2.15
Support: Support1: 1.36    Support2: 1.23
Resistance: Resistance1: 1.58    Resistance2: 1.84
Pivot: 1.4
Moving Average: MA(5): 1.46     MA(20): 1.42
MA(100): 1.16     MA(250): 1.8
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 60.7     %D(3): 64.5
RSI: RSI(14): 56.4
52-week: High: 5.25  Low: 0.79
Average Vol(K): 3-Month: 947 (K)  10-Days: 1,006 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PRAX ] has closed below upper band by 24.3%. Bollinger Bands are 19.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.46 - 1.47 1.47 - 1.47
Low: 1.36 - 1.37 1.37 - 1.38
Close: 1.4 - 1.42 1.42 - 1.43

Company Description

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Headline News

Tue, 19 Sep 2023
Truist Securities Initiates Coverage of Praxis Precision Medicines ... - Nasdaq

Tue, 19 Sep 2023
APLS, RXT and KLR among pre-market gainers - Seeking Alpha

Tue, 19 Sep 2023
Praxis Precision Medicines (NASDAQ:PRAX) Receives New ... - MarketBeat

Tue, 19 Sep 2023
Praxis Precision Medicines Inc (PRAX) Up 10.56% in Premarket Trading - InvestorsObserver

Wed, 06 Sep 2023
Should Biotechnology Stock Praxis Precision Medicines Inc (PRAX) Be in Your Portfolio Wednesday? - InvestorsObserver

Thu, 31 Aug 2023
Praxis Precision Medicines to Present Data from Epilepsy Portfolio ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 129 (M)
% Held by Insiders 7.075e+007 (%)
% Held by Institutions 8.3 (%)
Shares Short 2,950 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.5938e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -10
Return on Assets (ttm) 914.8
Return on Equity (ttm) -63.7
Qtrly Rev. Growth 1.46e+006
Gross Profit (p.s.) 0
Sales Per Share -43.8
EBITDA (p.s.) 0
Qtrly Earnings Growth -3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -138 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.04
Price to Cash Flow 5.27

Stock Dividends

Dividend 0
Forward Dividend 2.72e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.